Sent by e-mail only: XXXXXXXXXXXXXXXXXXXXXXXX

FAO XXXXXXXXXXXXXXX

Vitiligo Society

27 August 2024

Dear XXXXXXXXXX

**Re:** **Final Draft Guidance For Ruxolitinib Cream For Treating Non-Segmental Vitiligo In People 12 Years And Over [ID 3998]**

Thank you for your email of 22 August 2024, confirming you have no further comments in response to my initial scrutiny views in my letter of 8 August 2024.

I confirm your valid appeal points are:

* 1(a).1;
* 1(a).2;
* 1(a).3.

NICE shares the valid appeal grounds of each appellant with the other appellants to assist with preparation for the hearing.

NICE will be in contact with you regarding the administration of the appeal, which will be held orally.

Yours sincerely

XXXXXXXXXXXXXXX

Dr Mark Chakravarty

Lead Non-Executive Director for Appeals & Vice Chairman

National Institute for Health and Care Excellence